Author: Sundaram, Appavu K.; Ewing, Daniel; Liang, Zhaodong; Jani, Vihasi; Cheng, Ying; Sun, Peifang; Raviprakash, Kanakatte; Wu, Shuenn-Jue; Petrovsky, Nikolai; Defang, Gabriel; Williams, Maya; Porter, Kevin R.
Title: Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice Cord-id: fiwhgdef Document date: 2021_5_19
ID: fiwhgdef
Snippet: The development of a safe and effective vaccine to protect against COVID-19 is a global priority due to the current high SARS-CoV-2 infection rate. Currently, there are over 160 SARS-CoV-2 vaccine candidates at the clinical or pre-clinical stages of development. Of these, there are only three whole-virus vaccine candidates produced using β-propiolactone or formalin inactivation. Here, we prepared a whole-virus SARS-CoV-2 vaccine (SARS-CoV-2 PsIV) using a novel psoralen inactivation method and e
Document: The development of a safe and effective vaccine to protect against COVID-19 is a global priority due to the current high SARS-CoV-2 infection rate. Currently, there are over 160 SARS-CoV-2 vaccine candidates at the clinical or pre-clinical stages of development. Of these, there are only three whole-virus vaccine candidates produced using β-propiolactone or formalin inactivation. Here, we prepared a whole-virus SARS-CoV-2 vaccine (SARS-CoV-2 PsIV) using a novel psoralen inactivation method and evaluated its immunogenicity in mice using two different adjuvants, alum and Advax-2. We compared the immunogenicity of SARS-CoV-2 PsIV against SARS-CoV-2 DNA vaccines expressing either full-length or truncated spike proteins. We also compared the psoralen-inactivated vaccine against a DNA prime, psoralen-inactivated vaccine boost regimen. After two doses, the psoralen-inactivated vaccine, when administered with alum or Advax-2 adjuvants, generated a dose-dependent neutralizing antibody responses in mice. Overall, the pattern of cytokine ELISPOT responses to antigen-stimulation observed in this study indicates that SARS-CoV-2 PsIV with the alum adjuvant promotes a Th2-type response, while SARS-CoV-2 PsIV with the Advax-2 adjuvant promotes a Th1-type response.
Search related documents:
Co phrase search for related documents- acid level and logical approach: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant alum: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute sars cov respiratory syndrome coronavirus and adjuvant delta inulin: 1
- acute sars cov respiratory syndrome coronavirus and adjuvant group: 1
- acute sars cov respiratory syndrome coronavirus and logical approach: 1, 2
- acute sars cov respiratory syndrome coronavirus and long term immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- adjuvant alum and little neutralizing antibody response: 1
- adjuvant alum and long term immunity: 1, 2
- adjuvant alum combination and long term immunity: 1
Co phrase search for related documents, hyperlinks ordered by date